Fund+
Venture capital · Leuven, Belgium · Europe
Fund+ is a Belgian investment fund that invests in innovative life sciences companies, primarily in therapeutics, as well as diagnostics and medical devices. It was founded in 2015 by the Désiré Collen private foundation and Life Sciences Research Partners, and has raised €200 million in financing commitments.
Invests inHealthcare & Biotech
In its own wordslife sciencestherapeuticsdiagnosticsmedical devicesbiotechhealthcare
Your fit with Fund+
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsFund+ lists 13 checked portfolio companies on its own site and is named in 1 funding round. Its most frequent entry is Series B, 100% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 63% of its companies are based in Belgium. It invests most often alongside PMV, V-Bio Ventures and Kurma Partners.
Counts come from funding rounds that name Fund+, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Fund+'s whole history. Rounds on record name 1 company; its own site lists 13. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 0% |
| Series B | 100% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 0 | 0 |
| '26 | 1 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 33th | 13 companies |
| Recent activity | 59th | 1 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 72th | 8% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 70th | 4 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| PMV | 4 |
| V-Bio Ventures | 4 |
| Kurma Partners | 3 |
| Noshaq | 3 |
| BioGeneration Ventures | 2 |
| Qbic | 2 |
| VIVES | 2 |
| Ysios Capital | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers13100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Fund+ head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Funds
from public registers and its siteRecent portfolio activity
when companies last raised with Fund+| Date | Company | Stage |
|---|---|---|
| 4 Jun 2026 | Series B |
Round details for Fund+
Amounts, full round histories and every co-investor in Fund+'s rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
13 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Astrivax Therapeutics develops immunotherapies to eliminate viruses that can cause cancer | Healthcare & Biotech | Portfolio page | ||
| Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare ocular and CNS diseases. | Healthcare & Biotech | Portfolio page | ||
| Confo Therapeutics is a clinical-stage company committed to identifying and accelerating novel medicines for metabolic and endocrine diseases. | Healthcare & Biotech | Portfolio page | ||
| Egle Therapeutics develops precision medicines that modulate regulatory T cells to treat autoimmune diseases and cancer. | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Etherna is a platform driven RNA-LNP technology company that partners with pharma and biotech organizations developing nucleic acid–based therapeutics | Healthcare & Biotech | Portfolio page | ||
| ExeVir Bio develops novel antibody therapies to prevent and treat infectious diseases. | Healthcare & Biotech | Portfolio page | ||
| EyeD Pharma is a clinical stage pharmaceutical company developing innovative therapeutic solutions for ophthalmic diseases | Healthcare & Biotech | Portfolio page | ||
| Indigo is developing a continuous multi-metabolite monitoring system for people living with chronic diseases. | Healthcare & Biotech | Portfolio page | ||
| Minoryx Therapeutics discovers and develops novel treatments for severe orphan diseases of the central nervous system | Healthcare & Biotech | Portfolio page | ||
| Novadip Biosciences develops regenerative tissue products for bone and tissue repair | Healthcare & Biotech | Portfolio page | ||
| Ona Therapeutics develops first-in-class antibody drug conjugates to treat advanced cancer. | Healthcare & Biotech | Jun 2026Series B | Page + round | |
| Portfolio page |
About this data
site last read 8 Nov 2026- Site
- fundplus.be
- Last read
- 8 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 4 Jun 2026
- Companies checked
- 13
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Fund+'s profile as data
Pull Fund+'s portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/fundplus.be
# also
GET /v1/firms/fundplus.be/portfolio
GET /v1/firms/fundplus.be/coinvestors
GET /v1/firms/fundplus.be/news